JP2018527903A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527903A5
JP2018527903A5 JP2018502692A JP2018502692A JP2018527903A5 JP 2018527903 A5 JP2018527903 A5 JP 2018527903A5 JP 2018502692 A JP2018502692 A JP 2018502692A JP 2018502692 A JP2018502692 A JP 2018502692A JP 2018527903 A5 JP2018527903 A5 JP 2018527903A5
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018502692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527903A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/043712 external-priority patent/WO2017015622A2/en
Publication of JP2018527903A publication Critical patent/JP2018527903A/ja
Publication of JP2018527903A5 publication Critical patent/JP2018527903A5/ja
Pending legal-status Critical Current

Links

JP2018502692A 2015-07-22 2016-07-22 Gdf11結合タンパク質およびその使用 Pending JP2018527903A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562195504P 2015-07-22 2015-07-22
US62/195,504 2015-07-22
US201662275068P 2016-01-05 2016-01-05
US62/275,068 2016-01-05
PCT/US2016/043712 WO2017015622A2 (en) 2015-07-22 2016-07-22 Gdf11 binding proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2018527903A JP2018527903A (ja) 2018-09-27
JP2018527903A5 true JP2018527903A5 (cg-RX-API-DMAC7.html) 2019-10-17

Family

ID=57834686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018502692A Pending JP2018527903A (ja) 2015-07-22 2016-07-22 Gdf11結合タンパク質およびその使用

Country Status (6)

Country Link
US (1) US20180208648A1 (cg-RX-API-DMAC7.html)
EP (1) EP3324996A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018527903A (cg-RX-API-DMAC7.html)
AU (1) AU2016297248A1 (cg-RX-API-DMAC7.html)
CA (1) CA3031430A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017015622A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10722558B2 (en) 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
EP3562840A1 (en) * 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
US20200155481A1 (en) * 2017-05-03 2020-05-21 The Johns Hopkins University Intramuscular atovaquone for malaria prophylaxis
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス, インク.Flodesign Sonics, Inc. 音響トランスデューサドライバ及びコントローラ
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
RS62914B1 (sr) 2018-07-11 2022-03-31 Scholar Rock Inc Izoform selektivni inhibitori tgfbeta1 i njihova upotreba
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
WO2020023310A1 (en) * 2018-07-20 2020-01-30 Williams Eva Compositions of fcrn antibodies and methods of use thereof
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
AU2020412201A1 (en) * 2019-12-24 2022-07-14 Merus N.V. TGF-beta-RII binding proteins
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030167492A1 (en) * 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
ATE305036T1 (de) * 1994-07-08 2005-10-15 Univ Johns Hopkins Med Wachstums-differenzierungsfaktor-11
NZ509609A (en) * 1998-07-28 2003-11-28 Univ Johns Hopkins Med Disrupting growth differentiation factor-11 (GDF-11) to increase the muscle and bone tissue in animals
US20040136991A1 (en) * 2002-07-19 2004-07-15 Abbott Biotechnology Ltd. Treatment of anemia using TNFalpha inhibitors
JP5848861B2 (ja) * 2004-04-20 2016-01-27 ジェンマブ エー/エスGenmab A/S Cd20に対するヒトモノクローナル抗体
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2401293B1 (en) * 2009-02-24 2016-02-10 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
LT3904391T (lt) * 2010-03-10 2024-10-10 Genmab A/S Monokloniniai antikūnai prieš c-met
CA2852127C (en) * 2011-11-11 2020-10-27 Duke University Combination drug therapy for the treatment of solid tumors
WO2013148284A1 (en) * 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en) * 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
CA3023553A1 (en) * 2012-11-06 2014-05-15 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
EP2981822B1 (en) * 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays

Similar Documents

Publication Publication Date Title
JP2018527903A5 (cg-RX-API-DMAC7.html)
US20200079850A1 (en) Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
HRP20120477T1 (hr) Nova anti plgf protutijela
JP2019122405A5 (cg-RX-API-DMAC7.html)
US11787874B2 (en) Factor X binders enhancing FX activation
CA2869438A1 (en) Humanized tau antibody
JP2021501162A5 (cg-RX-API-DMAC7.html)
JP2017536354A5 (cg-RX-API-DMAC7.html)
JP2013091655A5 (cg-RX-API-DMAC7.html)
JP2020536532A5 (cg-RX-API-DMAC7.html)
RU2012119788A (ru) Связывающие il-1 белки
JP2017535257A5 (cg-RX-API-DMAC7.html)
RU2017137010A (ru) Анти-сеасам6 антитела и их применения
RU2017102514A (ru) Гуманизированные анти-тау-антитела
TW201323441A (zh) 抗tnf之雙特異性免疫結合物
JP2016527225A5 (cg-RX-API-DMAC7.html)
JP2024056687A5 (cg-RX-API-DMAC7.html)
WO2006055809A3 (en) Antibodies against vascular endothelial growth factor receptor-1
JP2016513664A5 (cg-RX-API-DMAC7.html)
JP2014503202A (ja) TNF−α結合性タンパク質
RU2010126078A (ru) Антитело против nr10 и его применение
JP2018510617A5 (cg-RX-API-DMAC7.html)
TW201204831A (en) Dual variable domain immunoglobulins and uses thereof
CN106573984A (zh) 针对mmp9的特异性抗体
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas